This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jan;15(1):3.

doi: 10.1038/nrurol.2017.202. Epub 2017 Nov 28.

Prostate cancer: H2A.Zac activates neo-enhancers

PMID: 29182604
DOI: 10.1038/nrurol.2017.202

Comment

Prostate cancer: H2A.Zac activates neo-enhancers

Clemens Thoma. Nat Rev Urol. 2018 Jan.

. 2018 Jan;15(1):3.

doi: 10.1038/nrurol.2017.202. Epub 2017 Nov 28.

Author

PMID: 29182604
DOI: 10.1038/nrurol.2017.202

No abstract available

PubMed Disclaimer

Comment on

Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.
Valdés-Mora F, Gould CM, Colino-Sanguino Y, Qu W, Song JZ, Taylor KM, Buske FA, Statham AL, Nair SS, Armstrong NJ, Kench JG, Lee KML, Horvath LG, Qiu M, Ilinykh A, Yeo-Teh NS, Gallego-Ortega D, Stirzaker C, Clark SJ. Valdés-Mora F, et al. Nat Commun. 2017 Nov 7;8(1):1346. doi: 10.1038/s41467-017-01393-8. Nat Commun. 2017. PMID: 29116202 Free PMC article.

References

1. Nat Commun. 2017 Nov 7;8(1):1346 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information